Clinical Observation And Mechanisms Of Chaihu-jia-Longgu-Muli-Decoction On Liver-qi Type Parkinson’s Disease With Depression

Objective:Observe the clinical effect of Chaihu-jia-Longgu-Muli-Decoction combined with benserazide on stagnation of liver-qi type Parkinson’s disease with depression (PDD) explore the possible mechanism of its treatment.Methods:selected 70 cases of PDD patients diagnose with syndrome of liver-qi stagnation,who received treatment from 2015.03 to 2015.12.Using random controlled method divided into treatment group and control group, each 35 patients. Patients of control group were treated by benserazide combine with Fluoxetine Hydrochloride Tablets; patients of treatment group were treated by CLMD combined with benserazide,3 months for a course. assess score of UPDRS Ⅰ scale, UPDRSⅢ scale, HAMD scale and ADL scale, before treatment and at week 4,8,12 during the course. Compare TCM syndrome score before and after treatment, evaluate clinical effect by Statistical analysis. Investigate the changes of serum 5-HT and NA; scale evaluate safety of medication. electrocardiogram to evaluate clinical effect.Result:1. General information:70 cases in this study divided into treatment group and control group, both 35 patients,2 cases drop out, drop out rate is 2.86%. Basic information from two group show no statistically significant differences (P>0.05).2. Score of UPDRS Ⅰ scale and UPDRSⅢ scale of PDD treated with CLMD combined with benserazide:UPDRS Ⅰ scale:To treatment group. UPDRS Ⅰ scale score between before treatment and in week 4,8,12, show statistically significant differences (P<0.05); while to control group, UPDRS Ⅰ scale score between weekO and in week 4,8 show no statistically significant differences (P>0.05). Compare treatment and control group, UPDRS Ⅰ scale score in week 4, 8,12 show statistically differences (P<0.05).UPDRSⅢ scale:UPDRSⅢ scale score in week 4 of two groups show no statistically significant differences (P>0.05), to treatment group, UPDRSⅢ scale score before treatment and in week 8,12, show statistically significant differences (P<0.05). while to control group, UPDRSIII scale score between week0 and in week 8,12 show no statistically significant differences (P>0.05). Compare treatment and control group, UPDRSⅢ scale score in week 4, 8,12 show statistically differences (P<0.05).3. HAMD scale score of PDD treated with CLMD combined with benserazide:There are difference between week 0 and week 4 of treatment group (P<0.05); HAMD scale score in week 4 of control group show no statistically significant differences (P>0.05). To both group, compare to week 0, the HAMD scale score significantly reduce in week 8,12, (P<0.05). Compare treatment and control group, HAMD scale score in week 4,8,12 show no statistically differences (P>0.05).4. ADL scale score of PDD treated with CLMD combined with benserazide:There are difference between week 8 and week 12 of both group (P<0.05); Compare treatment and control group, ADL scale score in week 4 show statistically differences (P<0.01); ADL scale score in week 8 show no statistically differences (P>0.05); ADL scale score in week 12 show statistically differences (P<0.05).5. The level changes of serum 5-HT and NA before and after treatment:After 12 weeks, 5-HT and NA level was both raised in two groups (P<0.05); but compare treatment and control group, changes of 5-HT and NA level show no statistically differences (P>0.05).6. TCM syndrome score of PDD treated with CLMD combined with benserazide:There are difference between before and after treatment of both group (P<0.01); Compare treatment and control group, TCM syndrome score between two group show no statistically differences (P>0.05).7. Dosage change of benserazide after treatment:At the end of trial, dose of benserazide all increased. To the treatment group, rate of increase was lower than control group, there are difference between tow group (P<0.05).8. Observation of side effect after treated with CLMD combined with benserazide:At the end of this trial, As to the TESS scale, treatment group was significantly lower than control group, there were difference between two group (P<0.05).Conclusions:To the PDD patient with stagnation of liver-qi, CLMD can obviously release mental behavior, emotion symptoms and motor symptoms; release depression symptoms during the early stage in the treatment; help PDD with liver-qi stagnation patients improve quality of life effectively, reduce TCM syndrome scores. Mechanisms of CLMD on PDD with liver-qi stagnation probably related to increase serum 5-HT and NA level, regulate the function of Monoamine neurotransmitter in neuron system.